Crossmark

Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

Crossref DOI link: https://doi.org/10.1016/j.eimce.2017.04.014

Published Print: 2018-05

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Rivero, Antonio

Pèc)rez-Molina, Josèc) Antonio

Blasco, Antonio Javier

Arribas, Josèc) Ramón

Asensi, Víctor

Crespo, Manuel

Domingo, Pere

Iribarren, Josèc) Antonio

Lázaro, Pablo

López-Aldeguer, Josèc)

Lozano, Fernando

Martínez, Esteban

Moreno, Santiago

Palacios, Rosario

Pineda, Juan Antonio

Pulido, Federico

Rubio, Rafael

Santos, Jesús

de la Torre, Javier

Tuset, Montserrat

Gatell, Josep M.
License Information

Text and Data Mining valid from 2018-05-01
More Information

This article is maintained by: Elsevier

Article Title: Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults

Journal Title: Enfermedades infecciosas y microbiologia clinica (English ed.)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eimce.2017.04.014

Content Type: article

Copyright: © 2017 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Document is current

Any future updates will be listed below